Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 4,276,018 shares, a growth of 251.3% from the June 15th total of 1,217,102 shares. Based on an average daily volume of 6,265,161 shares, the days-to-cover ratio is presently 0.7 days. Approximately 23.1% of the shares of the company are short sold.

Calidi Biotherapeutics Stock Performance

CLDI traded down $0.01 during trading on Tuesday, reaching $0.12. 3,026,371 shares of the company were exchanged, compared to its average volume of 3,050,548. Calidi Biotherapeutics has a 52 week low of $0.11 and a 52 week high of $10.92. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $0.17 and a 200 day moving average of $0.49. The stock has a market cap of $2.36 million, a P/E ratio of -0.02 and a beta of 1.30.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter.

Institutional Trading of Calidi Biotherapeutics

Several hedge funds have recently bought and sold shares of CLDI. Virtu Financial LLC bought a new position in Calidi Biotherapeutics in the 4th quarter worth about $25,000. Geode Capital Management LLC raised its holdings in shares of Calidi Biotherapeutics by 41.7% during the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after buying an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in shares of Calidi Biotherapeutics during the fourth quarter valued at approximately $173,000. 12.53% of the stock is currently owned by institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.